You might also wanna read
AstraZeneca adds another Chinese asset, from Dizal
AstraZeneca adds another Chinese asset, from Dizal Phil.Taylor Tue, 14/07/2026 - 10:31
pharmaphorum·2d ago
Senate bill seeks to curb US reliance on China in drug industry
US lawmakers are pushing for more scrutiny of Chinese investment in pharmaceuticals and biotechnology, as Washington’s strategic competition
South China Morning Post·1d ago
AstraZeneca CEO: ‘Biology will catch up with me at some point’
Long-serving pharma chief Pascal Soriot hopes research and risk-taking will secure growth in China and US
ft.com·4d ago
AstraZeneca compra a una farmacéutica de China los derechos de un medicamento pulmonar por 1.900 millones
Se trata de un inhibidor dual de PDE3/4 concebido para proporcionar efectos broncodilatadores y antiinflamatorios simultáneos.
20MINUTOS.ES·8d ago
AstraZeneca pens $2.1B Sino deal for challenger to Merck’s COPD drug Ohtuvayre
AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & Co.’s chronic ob
Fierce Biotech·8d ago
David Greene comments on EU-AstraZeneca dispute
AstraZeneca appears to be in danger of breaching its contract to supply the EU, and may have to renegotiate its contract to supply Covid-19
Edwin Coe·5y ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.